Literature DB >> 9355788

Acetorphan prevents cholera-toxin-induced water and electrolyte secretion in the human jejunum.

T A Hinterleitner1, W Petritsch, G Dimsity, H Berard, J M Lecomte, G J Krejs.   

Abstract

OBJECTIVES: Acetorphan is an orally administered inhibitor of enkephalinase in the wall of the digestive tract. It prevents inactivation of endogenous opioid peptides released by submucosal and myenteric neurons. The aim of this study was to examine the effect of acetorphan on jejunal water and electrolyte transport in healthy volunteers under basal conditions and in a state of intestinal secretion induced by a bacterial enterotoxin.
DESIGN: Ten volunteers in two groups were studied in an open trial. For the experimental design an intestinal perfusion technique was used.
METHODS: Cholera toxin was used to induce intestinal secretion in a model employing segmental perfusion of the human proximal jejunum. Acetorphan was given orally prior to intrajejunal administration of cholera toxin; its effect on intestinal transport was measured over a period of four hours after exposure to cholera toxin. Serum levels of methylthioether of thiorphan as the main metabolite were measured throughout three experiments to assure sufficient drug absorption.
RESULTS: Acetorphan had no influence on basal water and electrolyte absorption (133 vs. 140 ml/30 cm x h). In a control group with cholera toxin alone, significant water secretion was induced (131 ml/30 cm x h). Acetorphan completely prevented this secretion by leaving an absorption rate of 27 ml/30 cm x h. Intestinal electrolyte transport was also significantly changed towards absorption by acetorphan.
CONCLUSION: Acetorphan can prevent jejunal water and electrolyte secretion induced by cholera toxin. Enkephalins may thus protect the small intestine from enterotoxin-induced secretion.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9355788     DOI: 10.1097/00042737-199709000-00012

Source DB:  PubMed          Journal:  Eur J Gastroenterol Hepatol        ISSN: 0954-691X            Impact factor:   2.566


  9 in total

Review 1.  Enteroendocrine and neuronal mechanisms in pathophysiology of acute infectious diarrhea.

Authors:  Michael Camilleri; Sara Nullens; Tyler Nelsen
Journal:  Dig Dis Sci       Date:  2011-10-15       Impact factor: 3.199

Review 2.  Racecadotril.

Authors:  A J Matheson; S Noble
Journal:  Drugs       Date:  2000-04       Impact factor: 9.546

3.  A blind, randomized comparison of racecadotril and loperamide for stopping acute diarrhea in adults.

Authors:  Hwang-Huei Wang; Ming-Jium Shieh; Kuan-Fu Liao
Journal:  World J Gastroenterol       Date:  2005-03-14       Impact factor: 5.742

Review 4.  Treatment of infectious diarrhea in children.

Authors:  Nure H Alam; Hasan Ashraf
Journal:  Paediatr Drugs       Date:  2003       Impact factor: 3.022

Review 5.  Racecadotril versus loperamide: antidiarrheal research revisited.

Authors:  S Huighebaert; F Awouters; G N J Tytgat
Journal:  Dig Dis Sci       Date:  2003-02       Impact factor: 3.199

6.  Efficacy and tolerability of racecadotril in the treatment of cholera in adults: a double blind, randomised, controlled clinical trial.

Authors:  N H Alam; H Ashraf; W A Khan; M M Karim; G J Fuchs
Journal:  Gut       Date:  2003-10       Impact factor: 23.059

7.  A comprehensive review of the pharmacodynamics, pharmacokinetics, and clinical effects of the neutral endopeptidase inhibitor racecadotril.

Authors:  Marion Eberlin; Tobias Mück; Martin C Michel
Journal:  Front Pharmacol       Date:  2012-05-30       Impact factor: 5.810

Review 8.  A Comprehensive Comparison of the Efficacy and Tolerability of Racecadotril with Other Treatments of Acute Diarrhea in Adults.

Authors:  Wolfgang Fischbach; Viola Andresen; Marion Eberlin; Tobias Mueck; Peter Layer
Journal:  Front Med (Lausanne)       Date:  2016-10-14

Review 9.  Racecadotril in the treatment of acute diarrhea in children: a systematic, comprehensive review and meta-analysis of randomized controlled trials.

Authors:  Marion Eberlin; Min Chen; Tobias Mueck; Jan Däbritz
Journal:  BMC Pediatr       Date:  2018-04-03       Impact factor: 2.125

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.